Citigroup lifts PTC Therapeutics Inc. [PTCT] price estimate. Who else is bullish?

PTC Therapeutics Inc. [NASDAQ: PTCT] surged by $3.63 during the normal trading session on Wednesday and reaching a high of $61.68 during the day while it closed the day at $60.50. The company report on October 30, 2020 that PTC Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update.

– Evrysdi™ makes rapid progress with multiple international approvals and strong U.S. launch -.

– Total net revenue of $118.4 million, 66% YoY increase; Total net product revenue of $82.7 million, 16% YoY increase -.

PTC Therapeutics Inc. stock has also gained 15.30% of its value over the past 7 days. However, PTCT stock has inclined by 28.67% in the 3 months of the year. Over the past six months meanwhile, it has gained 28.97% and gained 25.96% year-on date.

The market cap for PTCT stock reached $4.23 billion, with 67.64 million shares outstanding and 65.71 million shares in the current float. Compared to the average trading volume of 585.13K shares, PTCT reached a trading volume of 1505563 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about PTC Therapeutics Inc. [PTCT]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PTCT shares is $60.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PTCT stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Citigroup have made an estimate for PTC Therapeutics Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on October 30, 2020. While these analysts kept the previous recommendation, UBS raised their target price to Neutral. The new note on the price target was released on October 28, 2020, representing the official price target for PTC Therapeutics Inc. stock. Previously, the target price had yet another raise to $71, while JP Morgan analysts kept a Overweight rating on PTCT stock.

The Average True Range (ATR) for PTC Therapeutics Inc. is set at 2.48, with the Price to Sales ratio for PTCT stock in the period of the last 12 months amounting to 13.58. The Price to Book ratio for the last quarter was 8.01, with the Price to Cash per share for the same quarter was set at 16.32.

PTCT stock trade performance evaluation

PTC Therapeutics Inc. [PTCT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 15.30. With this latest performance, PTCT shares gained by 21.88% in over the last four-week period, additionally plugging by 28.97% over the last 6 months – not to mention a rise of 49.38% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PTCT stock in for the last two-week period is set at 73.28, with the RSI for the last a single of trading hit 78.84, and the three-weeks RSI is set at 69.12 for PTC Therapeutics Inc. [PTCT]. The present Moving Average for the last 50 days of trading for this stock 50.08, while it was recorded at 55.69 for the last single week of trading, and 49.84 for the last 200 days.

PTC Therapeutics Inc. [PTCT]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and PTC Therapeutics Inc. [PTCT] shares currently have an operating margin of -62.80 and a Gross Margin at +87.04. PTC Therapeutics Inc.’s Net Margin is presently recorded at -81.95.

Return on Total Capital for PTCT is now -27.04, given the latest momentum, and Return on Invested Capital for the company is -36.22. Return on Equity for this stock declined to -53.24, with Return on Assets sitting at -18.34. When it comes to the capital structure of this company, PTC Therapeutics Inc. [PTCT] has a Total Debt to Total Equity ratio set at 55.19. Additionally, PTCT Total Debt to Total Capital is recorded at 35.56, with Total Debt to Total Assets ending up at 20.20. Long-Term Debt to Equity for the company is recorded at 50.96, with the Long-Term Debt to Total Capital now at 32.84.

Reflecting on the efficiency of the workforce at the company, PTC Therapeutics Inc. [PTCT] managed to generate an average of -$330,586 per employee. Receivables Turnover for the company is 4.97 with a Total Asset Turnover recorded at a value of 0.22.PTC Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.80 and a Current Ratio set at 4.90.

Earnings per share (EPS) analysis for PTC Therapeutics Inc. [PTCT] stock

With the latest financial reports released by the company, PTC Therapeutics Inc. posted -1.37/share EPS, while the average EPS was predicted by analysts to be reported at -0.51/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -168.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PTCT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for PTC Therapeutics Inc. go to -9.51%.

PTC Therapeutics Inc. [PTCT]: Insider Ownership positions

There are presently around $3,942 million, or 99.32% of PTCT stock, in the hands of institutional investors. The top three institutional holders of PTCT stocks are: WELLINGTON MANAGEMENT GROUP LLP with ownership of 8,023,699, which is approximately 28.623% of the company’s market cap and around 0.20% of the total institutional ownership; FMR LLC, holding 6,694,744 shares of the stock with an approximate value of $380.73 million in PTCT stocks shares; and VANGUARD GROUP INC, currently with $322.59 million in PTCT stock with ownership of nearly 1.67% of the company’s market capitalization.

Positions in PTC Therapeutics Inc. stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 125 institutional holders increased their position in PTC Therapeutics Inc. [NASDAQ:PTCT] by around 10,914,157 shares. Additionally, 81 investors decreased positions by around 5,794,166 shares, while 27 investors held positions by with 52,603,767 shares. The mentioned changes placed institutional holdings at 69,312,090 shares, according to the latest SEC report filing. PTCT stock had 33 new institutional investments in for a total of 1,537,553 shares, while 24 institutional investors sold positions of 1,567,695 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *



Download Free eBook For


100% free. stop anytime no spam



Download Free eBook For


100% free. stop anytime no spam